Hypoxia-inducible factor-1α gene polymorphisms and cancer risk: a meta-analysis
Tongfeng Zhao,Jing Lv,Jiangpei Zhao,Marius Nzekebaloudou
DOI: https://doi.org/10.1186/1756-9966-28-159
2009-01-01
Abstract:Background The results from the published studies on the association between hypoxia-inducible factor -1α (HIF-1α) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed to investigate the association between HIF-1α 1772 C/T and 1790 G/A polymorphisms and cancer. Methods The meta-analysis for 1772 C/T polymorphism included 4131 cancer cases and 5387 controls, and for 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. Allelic and genotypic comparisons between cases and controls were evaluated. Subgroup analyses by cancer types, ethnicity, and gender were also performed. We included prostate cancer in male subgroup, and female specific cancers in female subgroup. Results For the 1772 C/T polymorphism, the analysis showed that the T allele and genotype TT were significantly associated with higher cancer risk: odds ratio (OR) = 1.29 [95% confidence interval (CI, 1.01, 1.65)], P = 0.04, P heterogeneity < 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P = 0.003, P heterogeneity = 0.02, respectively. The effect of the genotype TT on cancer especially exists in Caucasians and female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, P heterogeneity = 0.02, and OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, P heterogeneity = 0.02, respectively. For the 1790 G/A polymorphism, the pooled ORs for allelic frequency comparison and dominant model comparison suggested a significant association of 1790 G/A polymorphism with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, P heterogeneity = 0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, P heterogeneity = 0.41, respectively. The frequency of the HIF-1α 1790 A allele was very low and only two studies were included in the breast cancer subgroup. Conclusions Our meta-analysis suggests that the HIF-1α 1772 C/T polymorphism is significantly associated with higher cancer risk, and 1790 G/A polymorphism is significantly associated with decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup, which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk for female specific cancers. The association between the 1790 G/A polymorphism and lower breast cancer risk could be due to chance.